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Abstract
Background: Atrial fibrillation (AF) is the most common arrhythmia worldwide. Despite effective treatment, it is
characterized by frequent recurrences. Optimal therapeutic management of AF requires active participation and
self-management from patients. Two major components of self-management are self-monitoring and sign-and-
symptom management. Pulse self-palpation (PSP) is a method of self-monitoring; however, not all AF patients are
capable of successfully performing PSP. Due to a lack of interventions on this topic, a nurse-led intervention for
patients with AF (PSPAF intervention) was developed to foster self-monitoring and to enhance self-management
through PSP. The purpose of this pilot study was to test the acceptability, feasibility, and potential effects of this
intervention on the capability of patients’ PSP and sign-and-symptom management. Moreover, we aimed at
gathering data on the feasibility of applied research methods to aid in the design of future studies.
Methods: The pilot trial involved 20 adult patients with AF, randomized to an intervention or usual care group. At
baseline and during a home visit 3–5 weeks later, we collected data using questionnaires, checklists, field notes, a
mobile ECG device, and a diary. Acceptability and feasibility measures were validated through predefined cut-off
points. Effect size estimates were expressed as relative risks (RR) and the number needed to treat (NNT).
Results: The PSPAF intervention seemed feasible, but only partly acceptable. There were limitations in terms of
potential effectiveness, suitability, addressing participants’ willingness to implement its content in daily life, and
adherence. Estimations of effect sizes suggest a large effect of the intervention on patients’ PSP capability (RR = 6.0;
95% CI = [0.83, 43.3]; NNT = 2.4), but almost no effect on sign-and-symptom management (RR = 1.5; 95% CI = [0.7,
3.1]; NNT = 4.0). The feasibility of applied research methods showed minor limitations on recruitment and
participant burden.
Conclusions: Despite some limitations, the intervention seemed to be applicable and promising. Taking into
account the suggestions and amendments we have made, we recommend conducting a full-scale trial to examine
the efficacy of the PSPAF intervention.
Trial registration: This pilot study was registered in the German Clinical Trials Register at September 4, 2017 (Main
ID: DRKS00012808).
Keywords: Atrial fibrillation, Pulse palpation, Pulse self-palpation, Self-management, Self-monitoring, Symptom
management, Nurse-led intervention, Pilot trial
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Background
Atrial fibrillation (AF) is the most common arrhythmia
worldwide [1, 2] with an estimated 33.5 million people
suffering from this illness [3]. The incidence and preva-
lence of AF increase, especially in the older population
[3]. AF is a chronic condition associated with an in-
creased risk of mortality [4], morbidity [5], as well as
cognitive decline and dementia [6]. It is one of the major
causes of stroke [5], impairs patients’ quality of life [7],
and can cause depression [8] in affected patients. In
addition, AF increases the economic burden of health
care systems [9] due to increased absences from work,
lower productivity [10], and higher utilization of health
care services [9, 11–13].
The primary goals of AF management include stroke
prevention, as well as heart rate and/or rhythm control
[5]. The treatment of AF is complex [14] and challen-
ging to manage in practice [15]. Furthermore, AF is
characterized by frequent recurrences [16] with rates
ranging from 22 to 83%, depending on therapy, time,
and study [17–22]. In order to achieve optimal thera-
peutic management of AF and minimize the risk of com-
plications, active patient participation is essential [23], as
well as emphasizing the importance of patients’ self-
management [24].
For the purpose of this study, we defined self-
management as an “individual’s ability, in conjunction
with family, community and the appropriate health care
professionals, to successfully manage the symptoms,
treatment, physical, psychosocial, cultural and spiritual
consequences and inherent lifestyle changes required for
living with a long-term chronic disease” ([24], p. 1145).
Effective self-management of chronic conditions encom-
passes cognitive decisions to maintain physiologic stabil-
ity as well as the recognition and response to symptoms
[25]. In addition, self-management is associated with
positive outcomes for patients and health care systems
[25–29]. According to Richard and Shea [25], the con-
cept of self-management is seen as an illness-related
process embedded in the more broader concept of self-
care. This, in turn, is associated with promoting and
maintaining health.
Incorporated in the domain of self-management are
the concepts of self-monitoring and symptom manage-
ment. Self-monitoring is defined as the “awareness of
symptoms or bodily sensations that is enhanced through
periodic measurements, recordings and observations to
provide information for improved self-management”
([30], p.343). For chronically ill patients, the recognition
of symptoms marks the beginning of the decision-
making process to which actions need to follow. Symp-
tom management, when performed by patients, is seen
as an element of self-monitoring and self-management
[25]. Its aim is the delay and prevention of negative
outcomes [31]. Besides symptoms as a subjective experi-
ence [31], signs are objective indications of a disease [32]
and are considered to be important for recognizing
problems [31]. The effective management of signs and
symptoms is a process that starts with detection and in-
terpretation, then leads to the selection of a strategy, and
ends with an evaluation of the chosen strategy [33]. The
manifestation and awareness of AF symptoms (such as
lethargy, palpitations, dyspnea, chest tightness, sleeping
difficulties, and psychosocial distress [5]) can vary greatly
from symptom-free to a massive impairment of daily life
[34–36]. AF recurrences can frequently be asymptom-
atic, and while patient reported symptoms are consid-
ered to be an inaccurate estimation [37], an irregular
pulse, regarded as a clinical manifestation of or sign for
AF, can be a measurable indicator of the disease or re-
currence [38, 39] that can be detected through pulse pal-
pation. In current guidelines, pulse palpitation is only
recommended to health care providers as a method for
screening individuals above the age of 65 [5] or as an as-
sessment method for patients with specific symptoms
[40]. Patient involvement in terms of pulse self-palpation
(PSP) has not yet been explicitly considered in any
guidelines.
PSP means feeling one’s own pulse wave with finger-
tips without the help of technical devices to determine
the rate, rhythm, and quality of the pulse [41]. PSP is a
simple, ubiquitous, non-invasive [42], cheap [43], useful,
and safe [44] method to identify an irregular pulse. In
studies, pulse palpation to assess heart rhythm has
shown a sensitivity of 76%, a specificity of 86% when
performed by the general population [45], and a rate-
dependent accuracy of 82–92% when performed by the
elderly [46]. A PSP by stroke patients unveiled a small
number of false-positive measurements and achieved a
sensitivity of 54% and a specificity of 96% [42].
Unfortunately, a limited number of AF-patients know
that AF can be detected by regular pulse palpation [47],
and even fewer are capable of performing PSP or in fact
do so [23, 48]. In order to fill this gap and to promote
patient involvement, it is recommended to educate pa-
tients with AF about PSP [49, 50].
Studies comprising PSP interventions focused on
screening for AF and only included participants without
AF [38, 42, 44, 45, 51, 52], but showed improvements in
technique and capability of PSP, with rates ranging from
69 [44] up to 100% [52] in the intervention groups.
These results suggest that inexperienced individuals can
successfully learn PSP without negative outcomes. Inter-
ventions especially designed for AF patients focusing on
self-management could not be identified in the pub-
lished literature. For this reason, the “Pulse Self-Palpa-
tion for patients with Atrial Fibrillation (PSPAF)”
intervention has been developed to foster self-
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monitoring and sign-and-symptom management, and
thus to enhance self-management.
Aims
The aim of this pilot trial was to test the PSPAF inter-
vention and to gather data towards designing a future
trial to test the efficacy of the intervention. Specific aims
were (1) to assess the acceptability and feasibility of the
intervention, (2) to assess the feasibility of research
methods and the perceived burden of study participa-
tion, and (3) to estimate a potential effect of the inter-
vention on the capability to perform PSP, and on sign-
and-symptom management.
Methods
Reporting on this pilot trial was guided by the recom-
mendations of the CONSORT statement extension to
randomized pilot and feasibility trials [53] (Reporting
checklist: see Additional file 1).
Design and setting
This single-center, single-blind randomized controlled
pilot trial was conducted on a ward with a focus on
heart rhythm diseases at an academic tertiary medical
heart center in Germany.
Participants, recruitment, and randomization
A sample of N = 20 participants (n = 10 per group) was
targeted. This sample size was based on suggestions in
the literature [54–56]. No formal sample size calculation
was conducted.
Patients were included if they (1) were hospitalized, (2)
had a diagnosis of paroxysmal or persistent AF, (3) were
at least 35 years of age, (4) lived within 30min by car
from the health care center, and (5) were able to read,
write, and understand German. Patients with (1) a cogni-
tive (e.g., dementia) or (2) a physical impairment of both
hands (e.g., peripheral polyneuropathy), (3) a third-
degree heart block or condition after AV nodal ablation
and an implanted pacemaker, (4) a life expectancy of less
than 2 months according to the physician, or (5) individ-
uals who had already taken part in any comparable edu-
cation program, were excluded.
Screening of potential participants via electronic health
records was carried out by the study coordinator. Eli-
gible participants were informed about the trial both
verbally and by written information. Patients who pro-
vided informed consent were randomized to either the
intervention group (IG) or the usual care group (UCG)
via sealed, opaque, and consecutively numbered enve-
lopes containing paper cards with the group allocation.
Group allocation was randomized by means of a
computer-generated blocked randomization procedure
with possible block sizes of 2, 4, 6, or 8 that were also
randomly specified [57]. The confidential preparation
and arrangement of envelopes was undertaken by a per-
son not involved in any stages of this trial.
Intervention
The nurse-led PSPAF intervention is a behavioral inter-
vention at an individual level for one or two recipients,
which can be referred to as “complex” due to several
interacting components [58]. The intervention was de-
veloped by a group of experienced nurses and advisory
cardiologists following the principles of action research
[59] and was based on the four sources of evidence [60]:
(1) empirical evidence, (2) clinical experience (involving
nurses, physicians, and other health experts), (3) con-
textual factors, and (4) patient preferences (field testing),
resulting in the creation of an intervention manual. For-
mal guidance of intervention development was retrieved
from the work of Sidani and Braden [61].
The PSPAF intervention consisted of five consecutive
components whose contents were presented orally in a
face-to-face session by a trained registered nurse (study
coordinator) using interactive teaching methods and
written materials. Four main topics were addressed: (1)
background information on the disease, pulse, and pulse
measurement; (2) learning the technique of PSP; (3) de-
termining heart rate and heart rhythm; and (4) interpret-
ation of values and possible actions. To illustrate the
mechanisms of the intervention, its active ingredients
were classified as intervention functions [62] with a set
of corresponding behavioral change techniques [63]. A
detailed description of the PSPAF intervention is pro-
vided in Table 1.
Variables and measurement
Variables and corresponding instruments are listed in
detail in Table 2. All instruments were developed specif-
ically for this study, based on literature or expert opin-
ion. Therefore, no external evidence exists on their
validity and reliability. In a cognitive pretest with nine
individuals (three AF patients, five healthy individuals,
one cardiac nurse), written study information, question-
naires, and the pulse diary were tested for clarity, read-
ability, and comprehensibility using verbal probing and
think-aloud interviews [64]. Vague or ambiguous items
and formulations were revised. Regarding applicability
and usability, field-note forms and checklists were ex-
plained to study assistants and discussed in advance with
one assistant. The checklist assessing the capability of
performing PSP and the vignettes assessing sign-and-
symptom management were discussed with two expert
nurses and one physician to gauge the accuracy of meas-
uring the respective concepts.
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Participant characteristics
Various socio-demographic and clinical characteristics
were assessed via a self-reported questionnaire (Q1).
Intervention acceptability
Acceptability was operationalized into five attributes
[61]: (1) appropriateness, (2) perceived effectiveness, (3)
perceived disadvantages of the intervention, (4) suitabil-
ity, (5) willingness, and (6) adherence. Attributes 1 to 5
were measured through a self-reported questionnaire
consisting of two parts (Q2.A.I and II) containing 11
items in total and that were framed based on the sugges-
tions of Francisco and Butterfoss [65]. Adherence to PSP
was measured based on the number of entries in a pulse
diary (D1) relative to the individual period between the
date of intervention and the home visit. This was calcu-
lated as the number of entries presented divided by the
number of possible entries. A participant was considered
to be adherent to PSP if ≥ 80% of the possible entries in
the pulse diary were filled out.
Intervention feasibility
Feasibility was operationalized into three components
[61]: (1) context/resources (i.e., the existence of enough
suitable rooms for delivering the intervention), (2) fidel-
ity of intervention implementation (i.e., clarity, compre-
hensiveness, and logical sequencing of the information
given to patients), and (3) time needed for delivering the
intervention. Context/resources were determined
through field notes (F2). In order to assess the fidelity of
intervention implementation and time for interventions,
every session was audiotaped. Recordings were then
rated by the principle investigator.
Research method feasibility
Feasibility of research methods was determined with re-
gard to three domains according to Thabane et al. [66]:
(1) process, (2) resources, and (3) management. The
domain process was comprised of the recruitment and
data collection processes. It was assessed through field
notes (F1) and a checklist (C0). Additionally, data were
collected on attrition. The extent of treatment
Table 1 Consecutive components and content of the PSPAF intervention with corresponding intervention functions and behavioral
change techniques
Components Function BCT Content in PSPAF
1) Information Education Information about
health consequences
Oral information about the pulse as a clinical sign, physiological and
pathophysiological values, and the significance of measurement of one’s own
pulse in terms of AF
2) Technique of a PSP Education Instruction on how to
perform a behavior
Explanation of the procedure of a PSP
Training Demonstration of the
behavior
Demonstration and joint exercise of the procedure of a PSP
3) Determination of heart
rate and heart rhythm
Training Instruction on how to
perform a behavior
Elucidations and examples on how to determine heart rate and heart rhythm
Training Demonstration of the
behavior
Demonstration and joint completion of how to determine heart rate and heart
rhythm
4) Interpretation, action,
and motivation
Training Instruction on how to
perform a behavior
Explanations on the interpretation of values
Enablement Action planning Explanations of what actions to take with different heart rates and rhythm
constellations
Training Behavioral practice/
rehearsal
Stand-alone repetition of a complete PSP procedure (technique, determination of
heart rate and heart rhythm, interpretation of values)
Training Habit formation Prompt to perform a PSP at least twice a day: in the morning after breakfast and
in the evening after dinner
Training Behavioral practice/
rehearsal
Emphasis on and motivation to practice PSP more than two times/day in the first
days after intervention
Enablement Verbal persuasion
about capability
Verbal positive reinforcement of participants PSP capability
5) Delivery of
supplementary material
Education Information about
health consequences
A fact sheet containing key information, illustrations, and explanation of the PSP
process, with recommendations regarding sign and symptom management in
the form of an algorithm displayed in a flowchart
Education Self-monitoring of
behavior
Provision and explanation of a pulse diary where the values of heart rate and
heart rhythm can be noted
BCT behavioral change techniques, PSP pulse self-palpation, PSPAF pulse self-palpation for patients with atrial fibrillation-intervention
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contamination [67] was assessed through a self-reported
questionnaire (Q2.C). Resources and management do-
mains were assessed by collecting data on the time spent
for recruitment and on the field notes made by study as-
sistants during home visits (F3).
Burden of study participation
Perceived burden of study participation was operational-
ized into the domains of psychological, physiological,
and financial burden [68] and was assessed through a
self-reported questionnaire (Q2.B).
Capability and sign-and-symptom management
Capability of performing PSP was operationalized into
nine components, where all had to be fulfilled in order
to rate a PSP as correctly performed. These components
referred to the three dimensions of quality, i.e., structure,
process, and outcome [69]. Capability was measured
through a checklist (C1) and a mobile ECG device (ME
90; Beurer GmbH, Ulm).
Sign-and-symptom management was operationalized
as the ability to correctly evaluate and respond to signs
and/or symptoms of AF and was assessed using vi-
gnettes. Vignettes “comprise stimuli that selectively por-
tray elements of reality to which research participants
are invited to respond” (p. 918) and can appear in differ-
ent forms [70]. They represent a practical, ethical, and
cost-effective method to generate data [71] and can be
used to assess perceptions, attitudes, and behaviors [70],
and were used in the context of self-care decision-
making [72]. For the purpose of this study, three dif-
ferent vignettes (V1–3) in written form were devel-
oped by the principle investigator and the study
coordinator taking into account the recommendations
of Hughes and Huby [73]. Each vignette briefly de-
scribed a situation that contained a statement to heart
rate and partly to symptoms in different severity
levels (V1—physiologic values, V2—mild pathologic
values, V3—severe pathologic values) and concluded
with the question how participants would behave in
this situation. Only one vignette at a time was pre-
sented to the participants for processing. The simul-
taneous processing of all three vignettes by all
participants would have made it possible to compare
them and thus facilitate their solution.
Vignettes were allocated during the randomization
process under the proviso of an equal distribution in
each group. In each group, V1 and V3 existed three
times and V2 existed four times in a random sequence.
Participants were considered capable of managing signs
and symptoms if they correctly solved the vignette rela-
tive to a standard solution (Vs1–3).
Procedures and data collection
Recruitment and follow-up took place between Septem-
ber 2017 and March 2018. After consent and
randomization, baseline data were collected for all study
participants (data collection point 1 = T1). Hereafter,
participants in the IG received the PSPAF intervention
and the pulse diary. After the session, participants in the
IG filled out questionnaire Q2.A.I. Additional field notes
(F2) were recorded by the study coordinator following
each session. Participants in the UCG received care as
usual, i.e., no education on pulse self-palpation.
In the first 2 weeks after enrollment, all participants
received a phone call from a study assistant to schedule
an appointment for a home visit (data collection point 2
= T2) within a period of 3–5 weeks after the interven-
tion. Prior to the home visit, questionnaires addressing
the acceptability of the intervention and the burden of
study participation (IG) or on treatment contamination
and the burden of study participation (UCG) were
mailed to participants. A study assistant blinded to
group allocation performed all home visits. During these
visits, participants of both groups were asked to perform
a PSP and their capability was assessed followed by an
ECG recording using the mobile device. The assigned vi-
gnette was then presented to participants and they were
asked to tell which action they would take in the
depicted situation. The answer given was then rated by
the study assistant with respect to the standard solution
(Vs1–3). Finally, pulse diaries (only IG) and question-
naires were collected. After every home visit, the study
assistant filled out a field note form (F3). A flowchart of
the study procedures is provided in Fig. 1.
Data analysis
Data were entered by the study coordinator. An inde-
pendent study assistant randomly selected 50% of data-
sets and screened them for data entry accuracy prior to
analysis. Potential entry errors were counted and cor-
rected. A rate of entry errors greater than 10% would
have had resulted in a complete revision and review of
all data sets. The data were analyzed according to the
intention-to-treat principle using IBM SPSS Statistics for
Windows, version 22 (IBM Corp., Armonk, N.Y., USA)
and Microsoft Excel 2013 (Microsoft, Redmond, Wash-
ington, USA).
Frequencies and percentages were calculated for all
variables as appropriate. Means and standard deviations
(SD) were calculated for normally distributed data. Me-
dians (Mdn) and interquartile ranges (IQR) were calcu-
lated for non-normally distributed data. Validation of
the acceptability and feasibility of the intervention, as
well as of the feasibility of research methods was ascer-
tained by predefined cut-off points (Table 2). Effect size
estimates were calculated for capability and sign-and-
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symptom management and expressed as relative risks
(RR) with 95% confidence intervals (CI) and as number
needed to treat (NNT). In case of a value of zero in any
cell of the contingency tables, we added plus one to
every cell to allow for RR calculation. Missing values
were descriptively summarized and their pattern was an-
alyzed using Little’s Missing Completely at Random test.
Cases with missing data were pairwise deleted in the re-
spective statistical analysis.
Results
Sample
For this study, a consecutive sampling approach was
used. Figure 2 shows participant flow throughout the
trial in a diagram according to the CONSORT statement
extension to randomized pilot and feasibility trials [53].
Details on screening and recruitment are described later
in the “Feasibility of research methods” section. The
sample consisted of 20 individuals (70% male) with a
mean age of 68.1 years (SD = 10.3; range = 43–84). Time
since the diagnosis of AF ranged from 0.04 to 24 years
(Mdn = 2.6; IQR = 0.2–8.8). Thirteen participants (65%)
were living with another person in the same household.
Sixteen participants (80%) held either a primary or a sec-
ondary school degree. Eight participants (40%) stated
having experiences with PSP and 16 (80%) possessed an
electronic device for pulse measurement. Six participants
(30%) measured their pulse once or multiple times a
day, whereas a quarter of participants (n = 5) had never
measured their pulse at home (Table 3).
Acceptability of the intervention
Immediately after the intervention (T1), participants of
the IG (n = 10) rated it as follows: very useful (50%), ra-
ther useful (40%), or partly useful (10%) and also very
important (80%) or rather important (20%). The inter-
vention was rather liked (30%) or very much liked (60%)
and all participants of the IG stated they would recom-
mend it to others. The intervention was rated as having
an accurate duration (100%), an easy level of difficulty
(90%), and as easy to comprehend (100%).
Fig. 1 Flowchart of study procedures. IG intervention group, UCG usual care group; C0, Q1, Q2, F1, F2, C1, V1-3, Vs1-3. pECG = assessment
instruments; T1, T2 = time points
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At T2, five participants (71.4%) of the IG (n = 7)
perceived the intervention as being helpful or very
helpful in dealing with AF in everyday life. No par-
ticipant perceived negative consequences in relation
to the intervention. However, one participant (14.3%)
did not know whether a negative consequence was
perceived or not. For 57.1% of the IG, the interven-
tion was very easy to implement into daily life. One
participant (14.3%) perceived it as partly easy/difficult,
whereas two participants (28.6%) had great difficulties
with the implementation into daily life. The self-
reported probability of continuing a daily PSP twice a
day was likely or very likely for 71.4% of the IG. All
negative ratings on T2 were made by the same
individuals.
Eight pulse diaries (80%) of the participants could be
collected. The median time between intervention and
home visit to observe the adherence to PSP was 26 days
(IQR = 25.5–32.0; range = 19–54). Four participants
(50%) filled out 87–100% of possible diary entries and
were therefore considered to be adherent to PSP. Four
participants (50%) were considered to be non-adherent
because only 0–47% of possible diary entries were com-
pleted (Fig. 3). Seven out of the 12 preliminary cut-off
points to validate acceptability of the intervention were
reached (Table 4).
Feasibility of the intervention
No relative was present during any of the intervention
sessions. The median duration of the interventions was
17:41 min (IQR = 15:40–19:19; range = 11:07–24:42).
The median rate of the fidelity of intervention imple-
mentation was 92.6% (IQR = 85.2–96.3; range = 70.4–
100). In eight of the intervention sessions, minor com-
prehension limitations were observed due to the use of
technical terms by the interventionist. In two sessions,
the cut-off rate (85%) was not reached due to compre-
hension problems in combination with minor deviations
in content. All preliminary cut-off points to validate the
feasibility of the intervention were reached (Table 5).
Feasibility of research methods
Recruitment process
Recruitment of participants was accomplished on 16
dates, with a respective minimum interval of 7 days be-
tween dates. In order to reach the target number of par-
ticipants, the recruitment phase lasted 134 days, exactly
12 days longer than the cut-off period of 4 months.
A total of 567 electronic health records or individuals
were screened and assessed for eligibility. Of these, 525 in-
dividuals (93%) were ineligible to participate in the trial.
Of 42 eligible patients, 20 consented to become partici-
pants, representing a recruitment rate of 50% (Fig. 1). The
Fig. 2 Participant flow diagram (referring to the CONSORT-Statement [53]). IG intervention group, UCG usual care group
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main reasons for refusal were (1) concerns that participa-
tion would be too burdensome, (2) no interest or doubts
about the meaningfulness of the intervention, or (3)
organizational reasons (i.e., immediate discharge or
transfer).
Eligibility criteria
The three most common inapplicable inclusion criteria
were “living within a 30min car ride to the participating
health care center” (449 times, 79.2%), “diagnosis of
paroxysmal or persistent AF” (279 times, 49.2%), and
“being able to read, write and understand German” (66
times, 11.6%). Moreover, 174 individuals (30.7%) were
excluded due to living outside the predefined geograph-
ical area. The most commonly occurring exclusion cri-
teria were “physical impairment of both hands” (22
times, 3.9%) and “cognitive impairment” (19 times,
3.4%). Additionally, 19 patients (3.4%) were excluded be-
cause of reasons not described in the exclusion criteria.
These reasons could be summarized in two categories:
(1) patient is sedated or on bedrest and/or (2) patient
could not be found in his/her room.
Follow-up and missing data
Overall, 18 participants (90%) attended the home visit at
T2. Two participants of the IG were unavailable for
scheduling a home visit, representing an attrition rate of
10%. Another participant from the IG did not complete
the questionnaires on T2, but took part in the home visit.
During a visit to a UCG participant, no ECG could be
recorded due to technical difficulties. Complete data sets
were available for 16 participants (80%) (IG, 7/70%;
UCG, 9/90%). Ultimately, there were no missing data for
T1, and at T2, the rate of missing data ranged from 10 to
30%. There was no consistent pattern for missing data.
Treatment contamination
Treatment contamination could not be observed. During
the study period, no participant of the UCG (n = 10)
took part in a PSP training, read or watched any media
containing elements of PSP training, or received advice
and/or training from a general practitioner to learn PSP.
Fig. 3 Adherence to PSP in the IG. IG intervention group, PSP
pulse self-palpation
Table 3 Demographic and clinical characteristics of study
groups
IG (n = 10) UCG (n = 10)
Mean age in years (SD, range) 65.8 (11.2,
43.0–78.0)
70.3 (9.3, 55.0–
84.0)
Median number of years with
diagnosis of AF (IQR, range)
0.9 (0.1–8.5,
0.04–20.0)
4.0 (0.8–10.0,
0.06–24.0)
Sex n (%)
Female 2 (20%) 4 (40%)
Male 8 (80%) 6 (60%)
Housing situation
Living alone 5 (50%) 2 (20%)
Living together with another
person
5 (50%) 8 (80%)
Highest educational qualification
None 0 (0%) 0 (0%)
Primary/main school 4 (40%) 4 (40%)
Secondary school 4 (40%) 4 (40%)
Polytechnic school 0 (0%) 0 (0%)
High school 1 (10%) 2 (20%)
University 1 (10%) 0 (0%)
Existing experience in PSP
Yes 3 (30%) 5 (50%)
No 7 (70%) 5 (50%)
Presence of an electronic device for pulse measurement at home
Yes 7 (70%) 9 (90%)
No 3 (30%) 1 (10%)
Regular implementation of pulse self-measurement at home
No 3 (30%) 2 (20%)
Multiple times a day 0 (0%) 1 (10%)
Once per day 3 (30%) 2 (20%)
Not daily, but multiple times per
week
3 (30%) 1 (10%)
Not every week, but multiple times
per month
1 (10%) 2 (20%)
Not every month, but multiple
times per year
0 (0%) 2 (20%)
IG intervention group, IQR interquartile range, PSP pulse self-palpation, SD
standard deviation, UCG usual care group
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Resources and management
During recruitment, the study coordinator had a time
exposure of 3–5 h per date of recruitment. Study assis-
tants accomplished 18 home visits. In total, study assis-
tants covered 416 km (Mdn = 35; IQR = 16.3–70.5;
range = 1–83) and had an overall time exposure of 1205
min (Mdn = 110; IQR = 90–148; range = 40–180) for
the home visits.
Burden of study participation
Overall, 15 out of 17 participants (88.2%) experienced
low or no burden throughout study participation. In the
UCG (n = 10), no (70%) or a low burden was perceived.
In the IG (n = 7), one participant experienced a very
high burden (psychological and physiological) and an-
other participant reported a partly (psychological) bur-
den. No participant reported a perceived financial
burden. Four out of the six preliminary cut-off points to
validate the feasibility of research methods were reached
at T2 (Table 6).
Capability
IG and UCG differed in terms of the capability of PSP.
Four participants (50%) of the IG (n = 8) and no partici-
pant of the UCG (n = 10) were considered capable of
performing PSP. This resulted in a RR of 6.0 (95% CI =
[0.8, 43.3]) and a NNT of 2.4. When comparing individ-
ual components of a PSP, the highest RR values were ob-
served for the reporting of the determined value of the
heart rhythm, and in determining heart rate and rhythm.
The lowest RR values were observed for performing a
PSP in the rest state and in reporting the determined
value of the heart rate (Table 7).
Table 4 Acceptability of the PSPAF intervention and cut-off points
Preliminary cut-off points Threshold
(%)
Observed values
(%)
Cut-off point
reached?
The PSPAF intervention was considered acceptable when participants…
1. Rated the intervention partly to very useful ≥ 75 100 Yes
2. Rated the intervention partly to very important ≥ 75 100 Yes
3. Liked the intervention partly to very much ≥ 75 100 Yes
4. Will eventually or definitively recommend the intervention to others ≥ 75 100 Yes
5. Rated the duration of the intervention as accurate ≥ 75 100 Yes
6. Rated the difficulty level of the intervention partly to very easy ≥ 75 100 Yes
7. Rated the comprehensibility of the intervention as partly to very high ≥ 75 100 Yes
8. Rated the intervention partly to very helpful concerning dealing with AF in everyday life ≥ 75 71.4 No
9. Did not experience any negative consequences related to the intervention ≥ 90 85.7 No
10. Rated implementation of the content of the intervention in daily life partly to very easy ≥ 75 71.4 No
11. Rated the likelihood of continuing a daily PSP twice a day as rather likely to very likely ≥ 75 71.4 No
12. Were considered adherent to PSP (> 80% of possible entries were filled out) ≥ 75 50.0 No
PSP pulse self-palpation, PSPAF pulse self-palpation for patients with atrial fibrillation intervention
Table 5 Feasibility of the PSPAF intervention and cut-off points
Preliminary cut-off points to valid-
ate the feasibility of the
intervention
Threshold Observed
values
Cut-off
point
reached?
1. Maximum timeframe for
delivering the intervention
30 min 17:41a,b
(max = 24:
42b)
Yes
2. Rate of fidelity to the
intervention protocol
≥ 85% 92.6%a Yes
3. Rate of intervention sessions
with appropriate and enough
room
≥ 85% 100.0% Yes
max maximum, PSPAF pulse self-palpation for patients with
atrial fibrillation-intervention
aMedian
bMinutes:seconds
Table 6 Feasibility of research methods and cut-off points
Preliminary cut-off points to valid-
ate the feasibility of research
methods
Threshold Observed
values
Cut-off
point
reached?
Recruitment of the target number
of participants (n = 20) within 4
months of study initiation (= 122
days)
122 days 134 days No
Attendance of intervention
participants in follow-up sessions
(home visits)
≥ 80% 90.0% Yes
Attrition rate ≤ 15% 10.0% Yes
Rate of complete data sets ≥ 80% 85.0%a Yes
Rate of treatment contamination ≤ 15% 0.0% Yes
Rate of participants having
perceived no or low burden of
study participation
≥ 90% 88.2% No
IG intervention group, UCG usual care group
aIG, 8/80% and UCG, 9/90%
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Sign-and-symptom management
Six participants (75%) of the IG (n = 8) and five of
the UCG (n = 10) solved the vignettes correctly,
resulting in a RR of 1.5 (95% CI = [0.7, 3.1]) and a
NNT of 4.0. Vignette V1 was solved correctly by all
four participants (IG: n = 1; UCG: n = 3) and V3 was
solved correctly by 83.3% (IG: n = 3; UCG: n = 2) of
the participants (n = 6). Vignette V2 was answered
incorrectly by 75.0% (IG: n = 2; UCG: n = 4) of the
participants (n = 8).
Discussion
In this pilot trial, the PSPAF intervention was tested
with respect to acceptability and feasibility. Moreover,
the feasibility of research methods and the burden of
study participation were assessed in combination with
the calculation of effect size estimates of PSP capabil-
ity and sign-and-symptom management. In summary,
the PSPAF intervention seemed to be feasible, but
only partly acceptable. The feasibility of applied re-
search methods highlighted some limitations. While
estimations of effect sizes seemed to correlate to an
effect of the intervention on the capability of per-
forming PSP, the effect on sign-and-symptom man-
agement remains unclear.
Acceptability and feasibility of the PSPAF intervention
The PSPAF intervention did not reach preliminary cut-
off points at T2; therefore, it could only be considered to
be partially acceptable. The intervention seemed appro-
priate and comprehensible and had no negative conse-
quences for participants. Yet it showed limitations in its
potential effectiveness, suitability, and in addressing par-
ticipants’ willingness of implementing its content into
daily life. The latter of which was also reflected in the
rate of adherence to PSP. Two individuals experienced
difficulties with including the intervention into daily life,
resulting in zero pulse diary entries. The lack of one-
third of the data at T2 on this outcome further hinders a
final judgment.
Overall, adherence to PSP was heterogenous, and two
different groups could be observed. One group was ad-
herent and the other was non-adherent to PSP. This dif-
fers from another pilot study [52] where 94% of
participants filled out more than 88% of possible diary
entries. Reasons for the lower rate in this study remain
unclear as corresponding data were not collected. We
hypothesize that self-efficacy (as a moderator and medi-
ator of all elements of self-management [25]) and motiv-
ation (as an essential element of healthy behavior [74])
differed in participants, ultimately affecting their adher-
ence. In addition, AF is associated with depression [8],
Table 7 Group comparison regarding capability of PSP
Components of PSP Rating IG (n = 8) n (%) UCG (n = 10) n (%) RR (95% CI)
1) PSP in rest Correct 5 (62.5) 4 (40.0) 1.6 (0.6–3.9)
Wrong 3 (37.5) 6 (60.0)
2) Use of a clock with second hand Correct 6 (75.0) 3 (30.0) 2.5 (0.9–6.9)
Wrong 2 (25.0) 7 (70.0)
3) Location of measurement Correct 6 (75.0) 4 (40.0) 1.8 (0.8–4.4)
Wrong 2 (25.0) 6 (60.0)
4) Technique of measurement Correct 6 (75.0) 2 (20.0) 3.8 (1.0–13.8)
Wrong 2 (25.0) 8 (80.0)
5) Duration of the measurement Correct 6 (75.0) 2 (20.0) 3.8 (1.0–13.8)
Wrong 2 (25.0) 8 (80.0)
6) Reporting determined value of the heart rate Yes 5 (62.5) 4 (40.0) 1.6 (0.6–3.9)
No 3 (37.5) 6 (60.0)
7) Reporting determined value of the heart rhythm Yes 4 (50.0) 0 (0.0) 6.0 (0.8–43.3)
No 4 (50.0) 10 (100.0)
8) Determined heart ratea Correct 5 (62.5) 1 (11.1) 5.6 (0.8–38.5)
Wrong 3 (37.5) 8 (88.9)
9) Determined heart rhythma Correct 4 (50.0) 0 (0.0) 5.5 (0.8–39.4)
Wrong 4 (50.0) 9 (100.0)
Overall PSP performance Correct 4 (50.0) 0 (0.0) 6.0 (0.8–43.3)
Wrong 4 (50.0) 10 (100.0)
IG intervention group, PSP pulse self-palpation, RR relative risk, UCG usual care group
aOnly nine cases were analyzed in UCG because of missing values due to technical problems with the mobile ECG
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which in turn could have negatively affected adherence
to self-monitoring [75]. Another possibility is a lower
perceived level of disease controllability, thus affecting
the willingness for regular self-monitoring [76]. Ideally,
the intervention should encompass these aspects.
The PSPAF intervention could be considered feasible.
It was completed within a short period of time, under-
lying its practicability in health care settings. However,
this is based solely on one pilot study in one local set-
ting. The fidelity of intervention implementation was
high. Nevertheless, minor limitations were observed des-
pite the interventionist being a co-developer of the inter-
vention with prior advanced knowledge of its
mechanisms and content.
Feasibility of research methods
Applied research methods could not be considered
feasible because of a longer-lasting recruitment phase
and an increased rate of burden throughout study
participation.
The transgression of the originally defined recruitment
phase was lower than 10% and might therefore be con-
sidered to be reasonable. The prolongation of the re-
cruitment phase was due to delays in recruitment:
numerous holidays during the recruitment phase and a
large number of ineligible patients further highlight re-
cruitment as one of the most common challenges in ran-
domized controlled trials [77]. Interestingly, other
studies with similar interventions showed lower recruit-
ment rates (15–33%) [44, 51, 52]. In our trial, one-third
of eligible individuals had to be excluded due to living
outside the predefined geographical area suggesting the
criterion to be too restrictive. However, given the con-
straints of this pilot study, including limited financial
and personnel resources, this could not have been al-
tered. Additionally, only half of eligible participants con-
sented to study participation. The assessment of reasons
for refusing participation aided in understanding why
potential participants declined [78]. These reasons taken
together, suggest that the potential disadvantages of par-
ticipation outweighed the benefits when deciding to par-
ticipate [79]. Furthermore, besides the supposition of a
potential burden, some eligible individuals were con-
cerned about the meaningfulness of the intervention.
Similar to the assumption of Koller et al. [80], the latter
could be partially attributed to the fact that clinical nurs-
ing research in Germany, especially at the study site, is
still quite novel. Patients are not familiar with this
branch of science and could have been reluctant to par-
ticipate. Adaptations and improvements of recruitment
strategies could perhaps change presuppositions of po-
tential participants towards perceiving studies to be
more beneficial, which could enhance recruitment rates
[77, 79, 81].
Two participants of the IG experienced a notable psy-
chological and physiological burden throughout study
participation. A comparable pilot study found a low rate
of participant burden [52]. However, the burden was not
specified as it was in our study and the participants ob-
tained monetary incentives for several data collection
points, potentially altering their experience. Due to the
subjective nature of perceiving burden [68] and since we
did not further investigate detailed reasons for these
kinds of burden, we can only speculate about potential
reasons.
In addition, the possible influence of the intervention
must be considered. Although no participant experi-
enced negative consequences from the intervention,
there could have been an effect on their perceptions. In
the literature, the following possible reasons are men-
tioned: proactive involvement with AF in terms of self-
management was distressing [82], and too much time
and cognitive efforts were required [64]. It must also be
considered that the two participants of the IG who were
lost to follow up did not continue participation because
of burden. Although definitive reasons for the burden of
study participation remain unknown, there are indica-
tions for potential burden that need to be monitored in
a future trial.
Effect size estimates
The probability of being capable of PSP was six times
greater in the IG compared to the UCG. The RR sug-
gests a large effect of the PSPAF intervention [83] con-
cerning the capability of carrying out PSP that is
considered to be clinically significant [84]. However, the
broad confidence interval reveals the inaccuracy of this
value and by including the value 1, there is a risk of no
effect at all. This also applies to the individual compo-
nents of a PSP. The small NNT [85] indicates that on
average, two patients would have had to receive the
PSPAF intervention (instead of usual care) for at least
one additional patient to be capable of performing PSP.
We might therefore assume, albeit with caution, that the
intervention could have improved this capability, which
is consistent with the findings of other studies with simi-
lar interventions [38, 44, 45].
With respect to sign-and symptom-management,
group differences were smaller. The probability of cor-
rectly solving the vignette was 50% greater in the IG
compared to the UCG. The RR suggests almost no effect
of the PSPAF intervention concerning sign-and-
symptom management knowledge [83], but it could also
be considered to be clinically significant [84]. Further-
more, the confidence interval includes the value 1, which
in turn implies no effect. The NNT indicates that on
average, four patients would have had to receive the
PSPAF intervention (instead of usual care) for at least
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one additional patient to show correct knowledge about
sign-and-symptom management. Although this ratio
seems to be acceptable [85], the effect of the interven-
tion seems questionable. Other studies have investigated
a similar outcome and observed greater effects but our
findings are hardly comparable due to differences in
operationalization [52] and/or methodology [38].
Limitations
The present study has several limitations. Consecutive
sampling and restrictive eligibility criteria reduced the
external validity of our results [86]. Furthermore, the
small sample size, which might be reasonable for a pilot
study [87], undermines statistical conclusion validity
[88]. Missing data and the practice of pairwise deletion
further contribute to this fact. In our study, it mostly af-
fected the determination and accuracy of effect sizes,
which in any case tend to be larger in pilot trials than in
a definitive trial [88]. Although pilot trials do not pro-
vide meaningful effect sizes [89], it is possible to investi-
gate the potential mechanisms of efficacy for a new
intervention [87]. Therefore, only an estimation of effect
sizes has been intended in our study but the results must
be regarded as preliminary and interpreted with caution.
Another limitation is the exclusive use of newly devel-
oped instruments for data collection without having in-
formation regarding the psychometric properties based
on systematic analysis. Although the instruments may be
considered to be face valid [90], and verbal probing as
well as think-aloud interviews can strengthen content
validity and the reliability of instruments [64], they can-
not be considered to be fully valid or reliable. This re-
sults in the potential of imprecise measurements, which
ultimately have implications on statistical conclusion val-
idity [91]. Above all, drawing inferences from diary en-
tries about adherence remains uncertain as evidence
indicates that some patients do not use diaries despite
recommendations [92]. The same is true for the use of
vignettes as indicators of sign-and-symptom manage-
ment. Despite their advantages in examining judgments
and decisions [93], their accuracy is unknown and ques-
tionable [88] and, thus, may have biased the results.
Lastly, it cannot be confirmed that the blinding of
study assistants was always maintained. Study partici-
pants may have imparted their group appointment to
the assistant and/or assistants may have drawn conclu-
sions due to improperly packed documents collected at
T2. These circumstances may have led to reduced ob-
jectivity of study assistants’ judgements [94], and pos-
sibly resulted in incorrect ratings.
Implications
Based on the results of this study, we formulate the fol-
lowing suggestions and recommendations regarding the
PSPAF intervention with a possible progression to a fu-
ture definitive trial.
The intervention could be enhanced with encouraging
elements to improve the motivation and adherence of
participants. Using elements of motivational interviewing
[74, 95], stressing the advantages of the intervention and
the diary [92] and encouraging an increased involvement
of relatives [75] could be conceivable. Furthermore, the
use of telephone calls shortly after the intervention
should be considered as a means to identify and address
difficulties of participants and facilitating implementa-
tion and adherence [75].
In order to allow for a larger sample, the inclusion cri-
terion limiting the geographical area should be adjusted.
Recruitment should be performed at different centers,
and recruitment strategies optimized through adaptation
of the written study information and personnel training.
At last, the relocation of the follow-up assessment to a
central location in combination with incentives for par-
ticipants should be considered in order to decrease the
number of or complete avoidance of home visits.
Participant burden should be monitored. The afore-
mentioned telephone call would offer the possibility to
identify and reduce patient burden. This topic will be
best addressed in a future qualitative sub-study to ex-
plore the specific burden of study participants.
The instruments assessing the main study outcomes
(capability, sign-and-symptom management, adherence)
must be evaluated for their validity and reliability, so as
to ensure precise measurements and valid statistical cal-
culations. The fidelity of intervention implementation
has to be ensured through careful training of interven-
tionists [96] and should optimally be monitored continu-
ously by two experts (rater, interrater), in order to
warrant a high level of objective ratings and a good qual-
ity of intervention implementation.
Procedures to support study blinding have to be
strictly observed in order to reduce the risk of bias. Data
collectors require careful briefing on this topic and study
participants need to be urged to not communicate infor-
mation regarding group appointment and/or received
intervention.
Further investigations should also include an analysis
of correlations between demographic and clinical char-
acteristics and outcomes, which could identify possible
determinants for outcome measures, as observed in
other studies [42, 44].
Conclusions
Results of the present pilot trial contribute to a better
understanding of the PSPAF intervention, afford a first
impression of its possible effects, and provide informa-
tion for planning a follow-up study. At large, the inter-
vention appears to be promising and applicable and
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could be optimized with a few adjustments. Due to
methodological restraints, the true effects of the inter-
vention remain vague and need to be further examined
in a fully powered trial. We recommend conducting a
full-scale trial with respect to the suggestions and
amendments mentioned above in an effort to ensure the
benefit and efficacy of the PSPAF intervention. For plan-
ning and conducting such a trial, investigators can use
the results obtained in this pilot trial.
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